Celcuity Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celcuity Inc. on February 24, 2021, covering events occurring on February 22, 2021, and February 23, 2021. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Minneapolis, Minnesota. The filing primarily addresses a new equity financing transaction and the termination of a prior sales agreement.
Key Financial Metrics and Transaction Details
- Equity Offering: The Company entered into a Purchase Agreement to sell 1,714,000 shares of common stock at a public price of $14.00 per share.
- Over-Allotment Option: The underwriter, Craig-Hallum Capital Group LLC, was granted a 30-day option to purchase up to an additional 257,100 shares.
- Net Proceeds: The offering is expected to generate approximately $22.4 million in net proceeds after deducting underwriting discounts and offering expenses.
- Use of Proceeds: Funds are designated for working capital, general corporate purposes, capital expenditures, research and development, clinical trial expenditures, and business development expansion.
- Terminated Agreement Proceeds: Under the terminated At Market Issuance Sales Agreement with B. Riley Securities, Inc., the Company had previously sold 20,807 shares for aggregate gross proceeds of $221,657.
Material Changes
The primary material change is the execution of a new underwritten public offering, replacing the previous "at the market" issuance strategy. Consequently, the Company voluntarily terminated its At Market Issuance Sales Agreement with B. Riley Securities, Inc., effective February 28, 2021. The new offering is expected to close on February 26, 2021, subject to customary conditions.
Outlook, Risks, and Management Commentary
Management intends to utilize the capital raised to advance clinical trials and expand business development activities. The filing notes that the Purchase Agreement contains customary representations, warranties, and indemnification obligations. The offering was made pursuant to an effective registration statement on Form S-3. No specific financial guidance or forward-looking revenue projections were included in this specific filing text.
Key Facts for Investor Verification
- Verify the closing of the offering on or around February 26, 2021, and the final number of shares sold, including any exercise of the over-allotment option.
- Confirm the exact net proceeds received after all transaction costs are finalized.
- Monitor the allocation of funds toward specific clinical trial milestones and R&D expenditures as outlined in the use of proceeds.
- Review the full text of the Purchase Agreement (Exhibit 1.1) for specific covenants and termination provisions.